Arresting cardiovascular disease progression. Early treatment may counteract high risk.
Cardiovascular disease (CVD) is currently the No. 1 cause of death in the United States and, with the exception of 1918, has held that position since 1900. At present, 64 million people in the United States have some form of CVD. The public health burden caused by CVD continues to affect the country in terms of cost, life expectancy, and hospital care.
Dallas Nephrology Associates, TX, USA. ramv@dneph.com
C Venkata S
CV
Ram
Pedro
P
Vergne-Marini
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D018849:Controlled Clinical Trials as Topic; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015995:Prevalence; D011322:Primary Prevention / Q000379:methods; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents